BridgeBio Pharma Inc
(FRA:2CL)
€
60.3
+0.020 (+0.03%)
Market Cap: 12.02 Bil
Enterprise Value: 13.40 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 66/100 BridgeBio Pharma Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2026 / 04:30PM GMT
Release Date Price:
€62.36
(+7.78%)
Eliana Merle
Barclays Capital Inc. - Analyst
Hi, everyone. Good afternoon. I'm Eli Merle, one of the biotech analysts here at Barclays. Very excited to have Neil Kumar here with us joining from BridgeBio. CEO. Thank you so much, Neil, for making the time.
Neil Kumar
BridgeBio Pharma Inc - Chief Executive Officer, Director
Thanks for having me. Really appreciate it.
Questions & Answers
Eliana Merle
Barclays Capital Inc. - Analyst
A lot to talk about across your four late-stage programs. Maybe just because it's topical now. Let's talk about what we learned yesterday from the team IP case.
Neil Kumar
BridgeBio Pharma Inc - Chief Executive Officer, Director
Sure. Yes, get right into it. So just as a reminder, this is an IP situation that is related to a competitor's drug products, Allstate relatively high level in and around it. But effectively, there are two key battlegrounds that I think people are paying attention to in the context of this trial and the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot